# Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/nivolumab-versus-everolimus-in-advanced-renal-cell-carcinoma/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Robert J. Motzer,Bernard Escudier,Ray McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Toni K. Choueiri,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Yoshihiko Tomita,Fabio A.B. Schutz,Christian Kollmannsberger,James Larkin,Alain Ravaud,Jason S. Simon,Li-An Xu,Ian M. Waxman,Padmanee Sharma |
| Citations | 5,921 |
| DOI | 10.1056/nejmoa1510665 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://www.nejm.org/doi/pdf/10.1056/NEJMoa1510665?articleTools=true |
| OpenAlex ID | https://openalex.org/W2222086386 |
| PMID | 26406148 |
| Type | article |
| Year | 2015 |

## Paper authors

- [Toni K. Choueiri](https://scholariq.org/researchers/toni-k-choueiri/)

## Paper journal

- [New England Journal of Medicine](https://scholariq.org/journals/new-england-journal-of-medicine/)

## Paper primary topic

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Paper topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Ferroptosis and cancer prognosis](https://scholariq.org/topics/ferroptosis-and-cancer-prognosis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.